Royce & Associates LP Sells 68,230 Shares of Harrow, Inc. (NASDAQ:HROW)

Royce & Associates LP reduced its stake in Harrow, Inc. (NASDAQ:HROW) by 18.9% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 292,090 shares of the company’s stock after selling 68,230 shares during the period. Royce & Associates LP owned about 0.82% of Harrow worth $9,800,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Quest Partners LLC bought a new stake in shares of Harrow in the third quarter worth about $29,000. AlphaQuest LLC lifted its holdings in Harrow by 452.8% in the 4th quarter. AlphaQuest LLC now owns 3,527 shares of the company’s stock worth $118,000 after buying an additional 2,889 shares during the period. China Universal Asset Management Co. Ltd. grew its position in shares of Harrow by 10.7% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 7,552 shares of the company’s stock worth $253,000 after buying an additional 727 shares during the last quarter. Virtu Financial LLC purchased a new position in shares of Harrow during the third quarter valued at approximately $271,000. Finally, Brookstone Capital Management bought a new position in shares of Harrow during the fourth quarter valued at approximately $275,000. Institutional investors own 72.76% of the company’s stock.

Analysts Set New Price Targets

Several analysts recently weighed in on the stock. B. Riley cut their price target on shares of Harrow from $73.00 to $69.00 and set a “buy” rating on the stock in a report on Wednesday, December 4th. HC Wainwright reaffirmed a “buy” rating and set a $57.00 target price on shares of Harrow in a research note on Tuesday.

Harrow Price Performance

HROW opened at $26.98 on Wednesday. The company has a current ratio of 1.55, a quick ratio of 1.44 and a debt-to-equity ratio of 3.23. The company has a market cap of $960.89 million, a price-to-earnings ratio of -28.70 and a beta of 0.69. The stock has a fifty day simple moving average of $30.01 and a two-hundred day simple moving average of $38.63. Harrow, Inc. has a 12-month low of $9.30 and a 12-month high of $59.23.

Harrow Profile

Harrow, Inc operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc and changed its name to Harrow Health, Inc in December 2018. Harrow Health, Inc was incorporated in 2006 and is headquartered in Nashville, Tennessee.